Unraveling the Links Between Cushing's Syndrome and Obesity with Repurposed Therapeutics

Abstract 

The clinical manifestations of Cushing's syndrome, a rare but life-threatening endocrine disorder caused by chronic glucocorticoid excess, frequently overlap with those of common obesity and metabolic syndrome. This diagnostic mimicry leads to significant delays in diagnosis and treatment, exposing patients to severe, long-term comorbidities. While both conditions are characterized by central adiposity, insulin resistance, and hypertension, the underlying molecular drivers are distinct: obesity is a multi-factorial metabolic disorder, whereas Cushing's syndrome stems from a singular hormonal excess. This review article explores the intricate molecular links that define cushing's syndrome and obesity, elucidating how hypercortisolism drives metabolic derangements at the cellular level. We delve into the pathophysiology of Cushingoid obesity, focusing on cortisol's direct effects on adipose tissue redistribution, its inhibition of key metabolic enzymes like AMP-activated protein kinase (AMPK), and its role in promoting insulin resistance. Recognizing the limitations of surgical and single-target therapies, we will examine the therapeutic potential of repurposing established, non-oncology drugs to address these specific metabolic comorbidities. By synthesizing evidence on agents like mifepristone, spironolactone, and even metformin, which modulate glucocorticoid action or downstream metabolic pathways, we aim to provide US healthcare professionals with a comprehensive perspective. This approach seeks to not only improve diagnostic accuracy by differentiating the two conditions but also to offer a new, molecularly targeted strategy for managing the complex and often refractory metabolic issues in patients with hypercortisolism obesity.

Introduction 

In the modern clinical landscape, the twin epidemics of obesity and metabolic syndrome represent a paramount public health challenge. For endocrinologists and primary care physicians alike, distinguishing simple obesity from more complex underlying endocrine disorders is a daily diagnostic puzzle. Among these, Cushing's syndrome stands as a formidable and often elusive masquerader. The cardinal features of this rare disorder, caused by chronic glucocorticoid excess, including central adiposity, a "moon face," and hypertension, are virtually indistinguishable from the classic presentation of common obesity. This profound clinical overlap contributes to a significant delay in diagnosis, exposing patients to devastating, and often irreversible, cardiovascular, metabolic, and psychiatric complications.

While both conditions are characterized by excessive fat accumulation, the fundamental pathophysiology is entirely different. Common obesity is a multi-factorial disease of energy imbalance, driven by genetics, lifestyle, and environmental factors. In contrast, Cushing's syndrome is a classic endocrine disease stemming from a singular, profound dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Yet, the two conditions are inextricably linked through a shared, albeit pathologically distinct, set of molecular pathways. Understanding this intricate relationship is paramount for moving beyond a simple visual diagnosis to a molecularly informed clinical practice.

The core of this relationship lies in cortisol's profound and multi-modal effects on metabolism. Cortisol, a powerful stress hormone, influences nearly every cell in the body. When present in excess, it directly promotes fat accumulation, particularly in the visceral, truncal, and facial compartments, the very features that define cushingoid obesity. Beyond fat redistribution, cortisol excess induces severe insulin resistance, glucose intolerance, and dyslipidemia, symptoms that are also central to metabolic syndrome. The result is a vicious cycle where hypercortisolism exacerbates obesity and its comorbidities, while the obesity itself can complicate diagnosis by mirroring the biochemical abnormalities of Cushing's. 

For years, the gold-standard treatment for Cushing's has been surgical resection of the underlying tumor (pituitary, adrenal, or ectopic). However, surgery is not always feasible, and in many cases, it is not curative. This reality necessitates a more nuanced approach to medical management, one that targets not only cortisol synthesis but also the downstream metabolic effects that are so detrimental to patient health. This review article aims to provide US healthcare professionals with a comprehensive look at the molecular mechanisms linking cushing's syndrome and obesity and to explore the therapeutic potential of repurposing old, established drugs. By leveraging the known pharmacology of agents approved for other conditions, we can offer a new perspective on managing the complex metabolic comorbidities of Cushing's syndrome, potentially improving long-term outcomes for patients with this challenging diagnosis.

Literature Review 

The molecular dialogue between hypercortisolism and metabolic dysfunction is a central theme in endocrinology. The literature provides a robust framework for understanding how cortisol excess, whether from endogenous or exogenous sources, orchestrates the clinical phenotype of cushingoid obesity and its associated comorbidities. This review synthesizes the key molecular mechanisms and explores the rationale for repurposing existing drugs to target these pathways.

Molecular Mechanisms of Adipose Tissue Dysfunction

The most visible sign of cushing's syndrome and obesity is the paradoxical redistribution of body fat, a key clinical feature that helps differentiate it from simple obesity. Cortisol's effects on adipose tissue are complex and depot-specific.

• Visceral Adiposity: Glucocorticoids preferentially increase fat deposition in the visceral and truncal depots while promoting lipolysis and fat loss in the subcutaneous limbs. This is mediated by differential expression of glucocorticoid receptors (GR) and the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which regenerates active cortisol from inactive cortisone, is more highly expressed in visceral adipose tissue. This local, tissue-specific amplification of cortisol's effects drives the hallmark central obesity.

• AMPK Inhibition: A groundbreaking study in 2025 revealed a novel mechanism linking cortisol excess to visceral fat accumulation. Researchers found that hypercortisolism inhibits AMP-activated protein kinase (AMPK) activity in visceral adipose tissue. AMPK is a master regulator of cellular energy, and its inhibition promotes fatty acid and lipid synthesis while suppressing their oxidation. This molecular derangement provides a direct explanation for the relentless visceral fat accumulation seen in Cushing's syndrome. 

Cortisol-Induced Insulin Resistance

Hypercortisolism is a potent driver of insulin resistance, a central feature of both cushing's syndrome and obesity.

• Impaired Insulin Signaling: Cortisol impairs insulin signaling at the cellular level by downregulating glucose transporter type 4 (GLUT4) in skeletal muscle and adipose tissue. This reduces glucose uptake from the bloodstream, leading to hyperglycemia and a compensatory increase in insulin secretion, which further exacerbates the problem.

• Increased Hepatic Glucose Production: Cortisol also promotes gluconeogenesis, the synthesis of new glucose in the liver. It achieves this by activating enzymes like phosphoenolpyruvate carboxykinase (PEPCK). This increased glucose output, combined with impaired peripheral uptake, creates a state of refractory hyperglycemia that is often difficult to manage. The severity of insulin resistance in Cushing's can be far greater than that seen in common obesity. 

Drug Repurposing: Targeting the Pathways

Traditional medical therapies for Cushing's syndrome (e.g., ketoconazole, metyrapone) primarily focus on inhibiting cortisol synthesis. However, these drugs can have significant side effects and do not always reverse the metabolic damage. The strategy of repurposed drugs Cushing's syndrome offers a promising alternative by targeting the downstream effects of cortisol excess.

• Mifepristone: Mifepristone, an approved medical treatment for Cushing's, is a classic example of drug repurposing. It was originally developed as a progesterone receptor antagonist but also acts as a powerful glucocorticoid receptor (GR) antagonist. By blocking cortisol from binding to its receptor, mifepristone effectively reverses the metabolic effects of hypercortisolism, even in the presence of high circulating cortisol levels. It has been shown to rapidly improve hyperglycemia and hypertension in patients with Cushing's, demonstrating the utility of targeting the receptor rather than the hormone itself.

• Metformin: Metformin, the most widely used drug for type 2 diabetes, is a compelling candidate for repurposing. Its primary mechanism is the activation of AMPK, the very pathway inhibited by cortisol. Given the newly discovered link, metformin's ability to restore AMPK activity in adipose tissue could theoretically mitigate visceral fat accumulation and improve insulin sensitivity in patients with hypercortisolism obesity. While not a direct treatment for Cushing's, it offers a molecularly sound approach to managing a central comorbidity.

• Spironolactone: Spironolactone, an aldosterone antagonist used for hypertension and hyperaldosteronism, has shown potential in Cushing's as well. It acts as a weak androgen receptor antagonist and also inhibits certain steroidogenic enzymes, including those in the adrenal glands. Some case reports suggest it can help manage the hypertension and hypokalemia seen in Cushing's, offering another example of a drug with established safety being applied to a new indication. 

The body of literature makes a strong case that the diagnosis and management of cushing's syndrome and obesity must go hand in hand. By understanding the specific molecular pathways through which cortisol drives metabolic dysfunction, clinicians can leverage the power of drug repurposing to provide a more targeted, effective, and personalized approach to patient care.

Methodology 

This review article was constructed through a systematic and comprehensive synthesis of existing scientific literature on the intricate relationship between hypercortisolism, metabolic dysfunction, and obesity. The primary objective was to provide US healthcare professionals with a consolidated, evidence-based resource that translates the growing body of knowledge on cushing's syndrome and obesity into a practical clinical framework for diagnosis and medical management. The review is a critical appraisal of published data, not a primary research study, meticulously curating information from major databases to inform a practical clinical perspective.

A rigorous search strategy was implemented across several major electronic databases, including PubMed, Scopus, and Web of Science. The search was conducted up to September 2025 to ensure the inclusion of the most current clinical guidelines, meta-analyses, and late-breaking research findings. The search utilized a combination of Medical Subject Headings (MeSH) and free-text terms to maximize the retrieval of relevant articles. Key search terms included: "cushing's syndrome and obesity," "cushingoid obesity," "hypercortisolism obesity," "adipose tissue dysfunction Cushing's," "repurposed drugs Cushing's syndrome," "cushing's syndrome diagnosis," "medical therapy Cushing's syndrome," "cortisol metabolism and obesity," "pituitary adenoma Cushing's," and "adrenal Cushing's syndrome."

Inclusion criteria for this review focused on human and animal studies published in the English language, including randomized controlled trials (RCTs), systematic reviews, meta-analyses, and large prospective cohort studies. Articles were selected based on their direct relevance to the molecular mechanisms linking hypercortisolism to metabolic dysfunction, diagnostic challenges, and the clinical outcomes of medical therapies, with particular emphasis on repurposed agents. We prioritized recent publications from high-impact journals that have provided new insights into the cellular mechanisms and clinical application of these drugs.

Exclusion criteria were applied to filter out editorials, case reports, and articles not directly related to the central theme of using repurposed drugs for the metabolic comorbidities of Cushing's. The initial search yielded several hundred results, which were then systematically screened by title and abstract for relevance. The full texts of all selected articles were retrieved and critically appraised for quality and contribution to the review's central themes. This meticulous approach to information gathering ensures that the discussion, results, and conclusions presented are well-supported by the most current and robust evidence available, serving as a reliable guide for clinical practice.

Results 

The systematic review of the literature reveals a clear and urgent need for new therapeutic approaches to managing the metabolic comorbidities in patients with Cushing's syndrome. The findings confirm that while surgery remains the first-line treatment, medical therapy, particularly with repurposed drugs, plays a vital role in addressing the profound metabolic derangements associated with hypercortisolism obesity.

Efficacy of Repurposed Drugs in Clinical Trials

The most compelling clinical evidence for a repurposed drug in this context comes from studies on mifepristone. The pivotal SEISMIC trial (Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing Syndrome) demonstrated significant improvements in clinical and metabolic parameters. A recent analysis from August 2025 confirmed that a majority of clinical responders required doses of ≥600 mg/day, with 35% needing ≥900 mg/day to achieve optimal benefit. The trial showed that mifepristone effectively antagonizes the glucocorticoid receptor, leading to rapid normalization of hyperglycemia, a key component of cushing's syndrome and obesity. This underscores the power of targeting the cortisol receptor directly, rather than just inhibiting its synthesis. While mifepristone is a cornerstone of medical therapy, its use is limited by side effects like hypokalemia and peripheral edema, and it can interfere with certain hormone assays.

Metformin for Insulin Resistance

While specific trials on metformin for Cushing's syndrome are limited, the evidence from other conditions provides a strong rationale for its use. Metformin, a first-line therapy for type 2 diabetes, improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), a central regulator of metabolism. This is particularly relevant given the new findings that cortisol inhibits AMPK in adipose tissue, a key driver of cushingoid obesity. Therefore, metformin’s mechanism of action directly counteracts a central pathological pathway of hypercortisolism. In patients with type 2 diabetes, metformin has been shown to be as effective as other agents in reducing blood glucose and is often associated with a modest weight loss or weight neutrality, making it an attractive adjunctive therapy to manage the severe insulin resistance and central adiposity that accompany Cushing's syndrome.

Spironolactone and Other Agents

Spironolactone, a potassium-sparing diuretic and aldosterone antagonist, has also been repurposed for managing certain comorbidities in Cushing's. The literature supports its use in treating refractory hypertension and hypokalemia, both common signs of mineralocorticoid excess in Cushing's. Its mechanism of action, by blocking mineralocorticoid receptors, can effectively control these symptoms. However, its use requires careful monitoring to prevent hyperkalemia, particularly in patients with renal impairment. Other repurposed agents under investigation, such as thiazolidinediones (e.g., pioglitazone), which improve insulin sensitivity, may also hold promise for addressing the profound metabolic dysregulation.

Comparative Efficacy and Safety

When compared to traditional steroidogenesis inhibitors like ketoconazole or metyrapone, repurposed drugs offer a different approach. The traditional inhibitors focus on reducing cortisol production, which can lead to other hormonal deficiencies and drug-drug interactions. In contrast, drugs like mifepristone and metformin target the downstream effects of cortisol. This molecularly targeted approach can lead to a more specific and rapid improvement in metabolic parameters without the risk of adrenal insufficiency seen with some synthesis inhibitors. While the side effect profiles of repurposed drugs are not benign, they are generally well-understood and more manageable for long-term use, making them valuable tools in the clinician's arsenal for patients who cannot undergo or have failed surgery. These results underscore the importance of a multifaceted approach to medical therapy Cushing's syndrome, one that not only controls cortisol levels but also actively reverses the associated metabolic damage.

Discussion 

The body of evidence reviewed here presents a compelling argument for a fundamental shift in the clinical paradigm for managing cushing's syndrome and obesity. For US healthcare professionals, this demands a more sophisticated diagnostic and therapeutic approach that moves beyond the simple visual presentation to a deeper understanding of the underlying molecular pathology. The profound diagnostic overlap between cushing's syndrome and obesity necessitates a high index of suspicion and a rigorous biochemical work-up for any patient presenting with features that are out of proportion to their weight gain or for those with refractory metabolic syndrome.

A major clinical implication is the recognition that Cushing's syndrome is not just about hypercortisolism but about the cascading metabolic effects it triggers. A patient who is clinically "cured" by surgical resection may still struggle with persistent central obesity, insulin resistance, and hypertension for years. This underscores the need for a sustained, multidisciplinary approach to cushingoid obesity and its comorbidities. The endocrinologist must work hand-in-hand with primary care physicians, cardiologists, and registered dietitians to manage these long-term issues. This is where repurposed drugs become invaluable.

The use of drugs like metformin and spironolactone in this context is not merely an off-label prescription; it is a molecularly sound therapeutic strategy. Metformin’s activation of AMPK directly counteracts a core mechanism of cortisol-induced lipogenesis and insulin resistance. Its use can help break the cycle of metabolic dysfunction, leading to a more complete recovery. Similarly, spironolactone's ability to manage hypertension and hypokalemia provides symptomatic relief while a more definitive treatment is sought. The challenge for clinicians is to integrate these repurposed agents into a coherent treatment plan, being mindful of their specific side effects and drug interactions.

The success of mifepristone, a repurposed anti-progestin, demonstrates that targeting the glucocorticoid receptor itself is a highly effective way to manage the disease’s effects. This principle can be extended to other, older drugs with known receptor-modulating or metabolic effects. The economic and practical benefits of this approach cannot be overstated. These drugs are generally inexpensive and widely available, which is a major advantage in a healthcare system grappling with rising costs. This accessibility makes them a viable option for a broader range of patients, particularly those who are not candidates for or have failed surgical intervention.

Ultimately, the future of medical therapy Cushing's syndrome lies in a personalized, stepwise approach. The gold standard will remain surgical resection of the tumor, but in cases of surgical failure, recurrence, or contraindication, medical management will become increasingly important. Repurposed drugs will likely form a central pillar of this management, offering targeted relief for a patient's most bothersome and dangerous comorbidities. The key for US healthcare professionals is to stay abreast of the evolving research, embrace a multidisciplinary mindset, and view these common, "old" drugs through a new, molecularly informed lens.

Conclusion 

The clinical and molecular overlap between cushing's syndrome and obesity presents a formidable diagnostic and therapeutic challenge. This review has highlighted the intricate ways in which chronic hypercortisolism drives metabolic dysfunction, leading to refractory central adiposity and insulin resistance. The strategy of repurposing old, established drugs offers a promising and molecularly sound approach to managing these severe comorbidities.

Agents like mifepristone, metformin, and spironolactone, which target either the glucocorticoid receptor or the downstream metabolic pathways, provide a powerful complement to surgical intervention and traditional therapies. They offer a targeted, cost-effective, and accessible way to reverse the profound metabolic damage caused by cortisol excess. As our understanding of the molecular links between cushing's syndrome and obesity continues to grow, so too will the therapeutic potential of these repurposed drugs. They are set to play an increasingly central role in the comprehensive, long-term care of patients with this complex endocrine disorder.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors